Compass Therapeutics Confirms Directors at Annual Meeting

Compass Therapeutics ( (CMPX) ) has issued an update.

On June 11, 2025, Compass Therapeutics, Inc. held its Annual Meeting of Stockholders where the election of three Class II directors was confirmed, securing their positions until the 2028 Annual Meeting. Additionally, the stockholders ratified the appointment of CohnReznick, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, indicating continued confidence in the company’s financial oversight.

The most recent analyst rating on (CMPX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Compass Therapeutics stock, see the CMPX Stock Forecast page.

Spark’s Take on CMPX Stock

According to Spark, TipRanks’ AI Analyst, CMPX is a Neutral.

Compass Therapeutics’ stock is moderately attractive, driven by strong market momentum and strategic leadership changes. However, significant operational losses, negative cash flows, and lack of current profitability weigh down the financial performance score. While technical indicators are positive, valuation remains a concern due to the negative P/E ratio.

To see Spark’s full report on CMPX stock, click here.

More about Compass Therapeutics

Compass Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of next-generation antibody therapeutics aimed at treating cancer and other serious diseases.

Average Trading Volume: 1,451,280

Technical Sentiment Signal: Buy

Current Market Cap: $347.1M

See more insights into CMPX stock on TipRanks’ Stock Analysis page.